As with chil­dren stud­ies, Su­per­nus AD­HD drug shows fast on­set of ac­tion in ado­les­cents

Pos­i­tive piv­otal da­ta on Su­per­nus’ $SUPN AD­HD drug in chil­dren gave in­vestors pause ear­li­er this month be­cause of the lack of dose re­sponse at the high­er 400 mg dose, which weighed on the shares. On Thurs­day, the drug de­vel­op­er fol­lowed up with large­ly sim­i­lar Phase III da­ta from an ado­les­cent study, but the drug’s swift on­set of ac­tion, as seen in pre­vi­ous tri­als with chil­dren, may be a key dif­fer­en­tia­tor from ex­ist­ing AD­HD non-stim­u­lant med­ica­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER